Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Ernest H Law"'
Autor:
Ernest H Law, Chris Cameron
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 12, Iss 6 (2023)
Externí odkaz:
https://doaj.org/article/3c0c392e7eef44d083576fbdfc5457f4
Autor:
Nadia A Nabulsi MPH, Khatija W Naing MPH, Huiwen Deng PharmD, MPH, Jenilee Cueto MPH, Alemseged A Asfaw PhD, Colin C Hubbard PhD, Jifang Zhou MD, MPH, PhD, Inyoung Lee MS, PhD, Debanjali Mitra MBA, MA, Gregory S Calip PharmD, MPH, PhD, Ernest H Law PharmD, PhD
Publikováno v:
Journal of Patient Experience, Vol 9 (2022)
This study describes health-related quality of life (HRQoL) among older Medicare beneficiaries with hormone receptor-positive (HR+) early breast cancer (eBC). Women aged ≥65 years diagnosed with stage I-III HR+ eBC between 1997 and 2014 using the S
Externí odkaz:
https://doaj.org/article/6cf80ecdd6f54a1990a0d26bf526f04e
Publikováno v:
Journal of Patient Experience, Vol 8 (2021)
Patient experience literature in early-stage breast cancer (eBC) is limited. This study used a mixed-methods approach to examine patient conversations from public online forums to identify and evaluate eBC-related themes. Among 60,000 eBC-related pos
Externí odkaz:
https://doaj.org/article/343d09b6ddef48868a6d4c9f57e27835
Autor:
Katie Mycock, Kent A. Hanson, Gavin Taylor-Stokes, Gary Milligan, Christian Atkinson, Debanjali Mitra, Salena Preciado, Ernest H. Law
Publikováno v:
Clinical Therapeutics. 44:1588-1601
Palbociclib was the first cyclin-dependent kinase 4/6 inhibitor approved by the US Food and Drug Administration for use in combination with aromatase inhibitors (AIs) as initial endocrine-based therapy or with fulvestrant in postmenopausal women who
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66560b67707ab61bd5468b11b892edbd
https://doi.org/10.1016/j.clinthera.2022.11.004
https://doi.org/10.1016/j.clinthera.2022.11.004
Publikováno v:
Medical Care. 60:462-469
Changes over time in health state values from a societal perspective may be an important reason to consider updating societal value sets for preference-based measures of health.The aim was to examine whether stated health preferences are different be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::476469bdae51fa903c62ce94624f83f9
https://doi.org/10.1097/mlr.0000000000001714
https://doi.org/10.1097/mlr.0000000000001714
Autor:
Ernest H. Law, Elena Galve-Calvo, Achim Wöckel, Rohan Parikh, Samantha K. Kurosky, Valerie Derrien Ansquer, Gaelle Frugier, Keith L. Davis, Elizabeth J. Esterberg, Olga Oikonomidou
Publikováno v:
Cancer Research. 82:OT2-19
Background: Palbociclib is currently the most commonly used cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) for patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in Eu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1799df6c478a3cbaca2747ee1e65c2ee
https://doi.org/10.1158/1538-7445.sabcs21-ot2-19-04
https://doi.org/10.1158/1538-7445.sabcs21-ot2-19-04
Autor:
Alemseged Ayele Asfaw, Debanjali Mitra, Jifang Zhou, J. Cueto, Naomi Y. Ko, Kent Hoskins, Nadia A. Nabulsi, Colin C. Hubbard, Ernest H. Law, Gregory S. Calip
Publikováno v:
The Breast : Official Journal of the European Society of Mastology
Breast, Vol 59, Iss, Pp 367-375 (2021)
Breast, Vol 59, Iss, Pp 367-375 (2021)
Background Multiple independent risk factors are associated with the prognosis of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC), the most common BC subtype. This study describes U.S. pop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c90dc44e7275856d2b81315020869b1
http://europepmc.org/articles/PMC8379689
http://europepmc.org/articles/PMC8379689
Autor:
Aaron Situ, J. Cueto, Chris Cameron, Imtiaz A. Samjoo, Abril Oliva Ramirez, Ernest H. Law, Elizabeth M. Salvo
Publikováno v:
Breast, Vol 57, Iss, Pp 5-17 (2021)
The Breast : Official Journal of the European Society of Mastology
The Breast : Official Journal of the European Society of Mastology
Background A systematic review and meta-analysis was conducted to assess breast cancer (BC) outcomes among patients with early-stage hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) BC, receiving adjuvant end
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aec920427520711c94adc99b20258fc
https://doi.org/10.1016/j.breast.2021.02.009
https://doi.org/10.1016/j.breast.2021.02.009
Autor:
Kathleen Beusterien, Bernadette Hallissey, Michael M Gaschler, Martine C Maculaitis, Ernest H. Law, Mary Lou Smith
Publikováno v:
Patient preference and adherence
Kathleen Beusterien,1 Martine C Maculaitis,2 Bernadette Hallissey,1 Michael M Gaschler,2 Mary Lou Smith,3 Ernest H Law4 1Kantar, Health Division, Horsham, PA, USA; 2Kantar, Health Division, New York, NY, USA; 3Research Advocacy Network, Plano, TX, US
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d8ae64ddbe819978661adc058d4d1ed
https://doi.org/10.2147/ppa.s298670
https://doi.org/10.2147/ppa.s298670
Autor:
Mayank Ajmera, Nadia Harbeck, Michelino De Laurentiis, Sabino De Placido, Keith L. Davis, Debanjali Mitra, Sara Y. Brucker, Ernest H. Law
Publikováno v:
Cancer Research. 80:P3-11
Background: Palbociclib is a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) that, when combined with an aromatase inhibitor (AI) or fulvestrant, has been shown in clinical trials to prolong progression-free survival (PFS) in patients with hormone re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::449444c6873411b42042ad19ceb0fe0a
https://doi.org/10.1158/1538-7445.sabcs19-p3-11-25
https://doi.org/10.1158/1538-7445.sabcs19-p3-11-25